Wilms' tumor medical therapy

Jump to navigation Jump to search

Wilms' tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Wilms' Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wilms' tumor medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wilms' tumor medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wilms' tumor medical therapy

CDC on Wilms' tumor medical therapy

Wilms' tumor medical therapy in the news

Blogs on Wilms' tumor medical therapy

Directions to Hospitals Treating Wilms' tumor

Risk calculators and risk factors for Wilms' tumor medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical therapy

This summary focuses on the NWTS (now COG Renal Tumor Committee) results and studies.

The major treatment and study conclusions of NWTS-1 through NWTS-5 (NWTS-1, NWTS-2, NWTS-3, NWTS-4, and NWTS-5) are as follows:

  • Routine, postoperative radiation therapy of the flank is not necessary for children with stage I tumors or stage II tumors with favorable histology (FH) when postnephrectomy combination chemotherapy consisting of vincristine and dactinomycin is administered.[127]
  • The prognosis for patients with stage III FH is best when treatment includes either (a) dactinomycin, vincristine, doxorubicin, and 10.8 Gy of radiation therapy to the flank; or (b) dactinomycin, vincristine, and 20 Gy of radiation therapy to the flank. Whole abdominal radiation is indicated for extensive intraperitoneal disease or widespread intraperitoneal tumor spill.[127]
  • The addition of cyclophosphamide at the protocol dose (10 mg/kg/d for 3 days every 6 weeks) to the combination of vincristine, dactinomycin, and doxorubicin does not improve prognosis for patients with stage IV FH tumors.[127]
  • A single dose of dactinomycin per course (stages I–II FH, stage I anaplastic, stage III FH, stages III–IV, or stages I–IV clear cell sarcoma of the kidney) is equivalent to the divided-dose courses, results in the same EFS, achieves greater dose intensity, and is associated with less toxicity and expense.[128]
  • Eighteen weeks of therapy is adequate for patients with stage I and II FH, whereas other patients can be treated with 6 months of therapy instead of 15 months.[99,125,128-130]
  • Tumor-specific loss of heterozygosity for combined 1p and 16q predicts recurrence of FH Wilms tumor.

There are two schools of thought as to the best therapy for Wilms' tumor. The National Wilms' Tumor Study (NWTS) has been studying this tumor in the United States since 1969. This group recommends surgery as the primary therapy for Wilms' tumor. They have carried out extensive research on this tumor which has been used to guide therapy, as well as to classify tumors into high and low risk groups based on molecular features and to estimate prognosis. [1]

The International Society of Paediatric Oncology in Europe, on the other hand, recommends preoperative chemotherapy to downstage the tumor prior to surgery to reduce the risk of intraoperative rupture of the tumor and dissemination of the malignant cells. A 4 week period of preoperative chemotherapy decreases the risk of intraoperative rupture of the tumor.


Stages I and II Initial therapy is with vincristine and actinomycin D(dactinomycin) in case of those with favorable histology. In recurrent cases as well as those with unfavorable histology, adriamycin(doxorubicin) is added to the regimen.

Stages III, IV, V Therapy is initiated with vincristine, actinomycin D(dactinomycin) and adriamycin(doxorubicin)

Etoposide, carboplatin and cyclophosphamide are added if necessary. Mesna(sodium 2-mercaptoethane sulfonate) is given with cyclophosphamide.

The current NWTS recommendations are as follows [2]


For tumors with favorable histology:
Stage I and II tumors - 18 weeks of therapy with Dactinomycin + Vincristine
Stage III and IV tumors - 24 weeks of therapy with Dactinomycin + Vincristine + Doxorubicin; as well as radiotherapy to tumor bed and involved sites
For tumors with unfavorable histology: Stage I - 18 weeks of therapy with Dactinomycin + Vincristine
Stages II -IV - 24 weeks of therapy with Dactinomycin + Vincristine + Doxorubicin + Cyclophosphamide + Etoposide; as well as radiotherapy to tumor bed and involved sites

The SIOP recommendations are as follows [2]

Stage I tumors of low grade - no chemotherapy necessary
Stage I tumors of intermediate grade or showing anaplasia - 18 weeks of therapy with Dactinomycin + Vincristine
Stage II without lymph node involvement - 28 weeks of therapy with Dactinomycin + Vincristine + Epirubicin
Stage II with lymph node involvement and Stage III - 28 weeks of therapy with Dactinomycin + Vincristine + Epirubicin; as well as radiotherapy to tumor bed
High grade tumors - 34 weeks of therapy with Epirubicin + Ifosfamide + Etoposide + Carboplatin; as well as radiotherapy
Stage IV (metastatic) - as per the appropriate local stage of the tumor; as well as treatment of metastases by surgery or radiotherapy


Recurrent tumors

ifosfamide, etoposide and carboplatin may be used.

Chemotherapy

Preoperative chemotherapy before nephrectomy is indicated in the following situations:

  • Synchronous bilateral Wilms tumor.
  • Wilms tumor in a solitary kidney.
  • Extension of tumor thrombus in the inferior vena cava above the level of the hepatic veins.
  • Tumor involves contiguous structures whereby the only means of removing the kidney tumor requires removal of the other structures (e.g., spleen, pancreas, or colon but excluding the adrenal gland).
  • Inoperable Wilms tumor.
  • Pulmonary compromise due to extensive pulmonary metastases.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
This image is provided by the National Library of Medicine.
File:XXXXX.png
This image is provided by the National Library of Medicine.

References

  1. http://www.nwtsg.org/about/about.html
  2. 2.0 2.1 Sushmita Bhatnagar (2009 Jan-Mar;). "Management of Wilms' tumor: NWTS vs SIOP". J Indian Assoc Pediatr Surg. Medknow Publications. 14: ((1)): 6–14. doi:doi: 10.4103/0971-9261.54811 Check |doi= value (help). PMC PMCID: PMC2809467 Check |pmc= value (help). PMID [PubMed 20177436[PubMed]] Check |pmid= value (help). Check date values in: |date= (help)

Template:WH Template:WS